UPDATE : Thursday, September 12, 2019
Court extends ‘temporary suspension’ of order to cancel Invossa trials
A local court has decided to temporarily suspend the legal effect of an adm...
by Jeong Sae-im  |  2019-07-26 17:50
SNUBH professor is 1st Asian keynoter at international Alzheimer meet
Professor Kim Sang-yun of Seoul National University Bundang Hospital has be...
by Lee Han-soo  |  2019-07-26 16:08
‘Kolon Life Science to start following up on Invossa-treated patients’
Kolon Life Science will conduct the first test on patients who received Inv...
by Lee Han-soo  |  2019-07-26 12:21
JW Creagene wins US patent for making dendritic cell treatment
JW Creagene said Thursday that it has obtained a patent for its source tech...
by Lee Han-soo  |  2019-07-25 16:39
Merck, Pfizer launch metastatic merkel cell carcinoma treatment in Korea
Merck and Pfizer will address the unmet medical need of patients suffering ...
by Lee Han-soo  |  2019-07-25 15:18
[Focus] Korean biopharmas eye US Humira market
Samsung Bioepis’s Humira biosimilar has secured entry into the U.S. market....
by Jeong Sae-im  |  2019-07-25 15:02
Kolon Life Science ends Invossa deal with Hong Kong partner
Kolon Life Science said it has terminated the supply agreement of Invossa-K...
by Lee Han-soo  |  2019-07-25 11:17
Tecentriq 1st immunotherapy to get coverage regardless of PD-L1 expression
Roche said Tecentriq, its immunotherapy treatment, will receive reimburseme...
by Lee Han-soo  |  2019-07-24 11:59
Alteogen to develop growth hormone for children with Brazilian partner
Alteogen said it has signed a licensing agreement with Cristalia, a Brazili...
by Lee Han-soo  |  2019-07-23 15:57
Hanmi's US partner to expand Poziotinib clinical program
Spectrum Pharmaceuticals, Hanmi Pharmaceutical's U.S. partner, said tha...
by Lee Han-soo  |  2019-07-23 14:25
Merck Biopharma Korea names new general manager
Merck Korea said that it has appointed Javed Alam as the new general manage...
by Lee Han-soo  |  2019-07-23 11:08
‘Doubts about biopharmaceutical-developing ability to change investment pattern’
Korea Investment & Securities said that it expects the investment sentiment...
by By Jeong Sae-im  |  2019-07-23 10:58
Will Gilead enter the autoimmune diseases market?
Gilead Sciences is highly likely to buy Otezla (apremilast), a new oral PDE...
by Kim Yun-mi  |  2019-07-22 17:34
Korean drugs strong in anti-reflux treatment market
Locally developed drugs are showing robust sales records in gastroesophagea...
by Jeong Sae-im  |  2019-07-22 15:15
JW completes P1 trials for target anticancer treatment
JW Pharmaceuticals said that it has presented phase 1a/1b clinical trial re...
by Lee Han-soo  |  2019-07-22 14:02
MedPacto passes tech assessment, seeks KOSDAQ listing this year
MedPacto, a subsidiary of Theragen Etex, is pushing be listed on the KOSDAQ...
by Jeong Sae-im  |  2019-07-19 17:01
Employees file suit against Galderma Korea
Galderma Korea has recently been sued by its labor union. The company’s lab...
by Kim Yun-mi  |  2019-07-19 15:41
‘Insurance benefits needed for Ibrance-fulvestrant combo treatment’
In Korea where the age of breast cancer patients is low, there is an urgent...
by Kim Yun-mi  |  2019-07-18 17:04
2 cancer immunotherapy makers face different situations in reimbursement talks
Bristol-Meyers Squibb (BMS) is reportedly having a hard time persuading its...
by Kim Yun-mi  |  2019-07-18 16:01
Bridge Biotherapeutics licenses out IPF treatment candidate to Boehringer
Bridge Biotherapeutics said that it has licensed out BBT-877, an idiopathic...
by Lee Han-soo  |  2019-07-18 15:58
Back to Top